MARKET

GILD

GILD

Gilead Sciences Inc
NASDAQ
65.68
-0.49
-0.74%
After Hours: 65.65 -0.03 -0.05% 19:59 05/24 EDT
OPEN
66.38
PREV CLOSE
66.17
HIGH
66.43
LOW
65.21
VOLUME
5.97M
TURNOVER
0
52 WEEK HIGH
87.87
52 WEEK LOW
64.33
MARKET CAP
81.83B
P/E (TTM)
182.65
1D
5D
1M
3M
1Y
5Y
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
Wells Fargo released its annual biopharma M&A screen for 2024. The investment bank identified 31 companies in the SMid-cap space that demonstrate a high or medium fit to large-cap pharmaceutical companies. Viking, CRISPR, Intellia among potential acquisition targets for AbbVie and Gilead.
Seeking Alpha · 19h ago
Catalyst Watch: Costco earnings, M&A drama, Viking ratings, and a key inflation read
Seeking Alpha's Catalyst Watch includes a breakdown of next week's key events. The stock markets will be closed on Monday for Memorial Day holiday. The most overbought stocks are Barnes & Noble Education and Solowin. The quiet period ends on Viking Holdings (VIK) on May 29. Capri Holdings will report earnings and there will be some M&A drama.
Seeking Alpha · 1d ago
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
Barron‘s · 1d ago
Dodge & Cox Stock Fund Q1 2024 Shareholder Letter
Dodge & Cox Stock Fund seeks long-term growth of principal and income. Equity markets rose to all-time highs during the first quarter of 2024, extending the robust performance of 2023. The Fund underperformed the S&P 500 and modestly trailed the Russell 1000.
Seeking Alpha · 1d ago
Should We Be Cautious About Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE Of 2.6%?
Return on equity (ROE) is a measure of how much a company can earn for its shareholders. The object is to determine how much profit is earned by the company. Gilead Sciences has a low return on equity due to its high level of debt. It uses a high amount of debt to invest in its business. We use the formula to compare the ROE of the company with its industry average.
Simply Wall St · 2d ago
Analysts’ Top Healthcare Picks: Scholar Rock Holding (SRRK), Gilead Sciences (GILD)
TipRanks · 2d ago
Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
Gilead Sciences has struggled with declining profits and sales in recent years. The company's growth potential lies in its HIV and oncology treatments. Gilead's 6% yield and 6% growth potential offer a long-term return potential of 10% to 11%. The company faces competition and disappointing trial results.
Seeking Alpha · 2d ago
Gilead Sciences (GILD) Gets a Hold from Wells Fargo
TipRanks · 4d ago
More
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

Webull offers Gilead Sciences, Inc. stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.